Low prevalence of antiretroviral drug resistance among HIV-1 seroconverters in London, 1984-1991

Journal of Infection

Volumn 44, Issue 2, 2002, Pages 88-91

  Easterbrook, P J ^a   Hertogs, K ^b   Waters, A ^a   Wills, B ^c   Gazzard, B G ^d   Larder, B ^b  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b Virco UK Ltd   (United Kingdom)

^c BRISTOL MYERS SQUIBB   (United States)

^d CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; PROTEINASE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; ZIDOVUDINE;

ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DNA POLYMORPHISM; GENE AMPLIFICATION; GENETIC ANALYSIS; GENOTYPE; HEALTH SURVEY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MUTATIONAL ANALYSIS; POPULATION GENETICS; PREVALENCE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS; SEROCONVERSION; UNITED KINGDOM; VIRUS MUTATION;

EID: 0036067140     PISSN: 01634453     EISSN: None     Source Type: Journal    
DOI: 10.1053/jinf.2002.0971     Document Type: Article

References (29)

1. Public health implications of anti-retroviral therapy and HIV drug resistance
2. Impact of drug resistance mutations on virologic response to salvage therapy
3. Drug-resistance genotyping in HIV-1 therapy: The Viradapt randomized controlled trial
4. Antiretroviral therapy in adults: Updated recommendation of the International AIDS Society USA panel
5. Establishment of new transmissable and drug-sensitive human immunodeficiency virus type 1 wild types due to transmission of nucleoside analogue resistant virus
6. Pol gene quasispecies of human immunodeficiency virus: Mutations associated with drug resistance in virus from patients undergoing no therapy
7. Large proportion of non-B HIV-1 subtypes and presence of zidovudine resistance mutations among German seroconverters
8. Prevalence of drug resistant mutants, and virological response to combination therapy in patients with primary HIV-1 infection
9. International perspectives on antiretroviral resistance. Nonnucleoside reverse transcriptase inhibitor resistance
10. HIV protease and reverse transcriptase variation and therapy outcome in antiretroviral-naïve individuals from a large North American cohort
11. Prevalence of HIV-1 drug resistance in antiretroviral naive patients: A prospective study
12. Reduced antiretroviral drug susceptibility among patients with primary infection
13. Prevalence of genotypic and phenotypic resistance to anti-retroviral drugs in a cohort of therapy naive HIV-1 infected US military personnel
14. Prevalence of mutations associated with reduced antiretroviral drug susceptibility among human immunodeficiency virus type 1 seroconverters in the United States, 1993-1998
15. Prevalence of HIV-1 resistant to antiretroviral drugs in 81 individuals newly infected by sexual contact of injecting drug use
16. HIV-1 drug resistance in newly infected individuals
17. Prevalence of primary HIV drug resistance among seroconverters during an explosive outbreak of HIV infection among injecting drug users
18. Prevalence of resistance mutations in antiretroviral naive chronically HIV-infected patients in 1998: A French nationwide study
19. Prevalence of genotypic resistance to nucleoside analogues in antiretroviral-naive and antiretroviral-experienced HIV-infected patients in Spain
20. Prevalence of drug resistance mutations in patients with primary HIV-1 infection
21. Single and multidrug resistance mutations to reverse transcriptase and protease inhibitors in human immunodeficiency virus type I infected patients from two geographical areas in Spain
22. Prevalence of genotypic resistance among antiretroviral drug-naive HIV-1 infected patients in Belgium
23. Detection of genotypically drug-resistance HIV-1 variance and non-B subtypes in recently infected antiretroviral naive adults in Italy
24. Antiretroviral drug-resistant genotypic mutations in HIV infected persons at first diagnosis (1988 to 1997)
25. Prevalence of AZT-resistant HIV-1 high in drug naive patients
26. Transmission of antiretroviral-drug-resistant HIV-1 variants
27. Low prevalence of antiretroviral drug resistance mutations in drug naive patients with established HIV infection in the UK
28. Prevalence of antiretroviral resistance in a South London cohort of treatment-naive HIV-1 infected patients
29. Analysis of prevalence of HIV-1 drug resistance in primary infections in the UK